Bjornstad, Petter
Roncal, Carlos
Milagres, Tamara
Pyle, Laura
Lanaspa, Miguel Angel
Bishop, Franziska K.
Snell-Bergeon, Janet K.
Johnson, Richard J.
Wadwa, R. Paul
Maahs, David M.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (T32DK06387, DK075360)
American Diabetes Association (7-13-CD-10)
JDRF (11-2007-694)
Article History
Received: 24 October 2015
Revised: 25 November 2015
Accepted: 9 December 2015
First Online: 23 December 2015
Compliance with ethical standards
: The study was approved by the Colorado Multiple Institution Review Board, and informed consent and assent (for subjects <18 years) were obtained from all subjects.
: Drs. Bjornstad, Roncal, Pyle Lanaspa, Snell-Bergeon, Wadwa, and Maahs and Ms. Harra and Bishop have no conflict of interest to disclose. Dr Johnson holds a patent related to lowering uric acid in the treatment of diabetic nephropathy and has shares with XORT therapeutics.
: Drs. Bjornstad, Pyle and Maahs are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.